Warfarin Is the Preferred Therapy for Patients With Thrombotic APS: Back to the Future
- PMID: 36328156
- DOI: 10.1016/j.jacc.2022.10.015
Warfarin Is the Preferred Therapy for Patients With Thrombotic APS: Back to the Future
Keywords: arterial thrombosis; bleeding; mortality; stroke; venous thromboembolism.
Conflict of interest statement
Funding Support and Author Disclosures Dr Crowther has received personal funding from AstraZeneca, Precision Biologicals, Hemostasis Reference Laboratories, Syneos Health, Bayer, Pfizer, and CSL Behring; and holds the Leo Pharma Chair in Thromboembolism research, which is endowed at McMaster University. Dr Jones is supported by a career development award from the National Heart, Lung, and Blood Institute (K23HL157751). Dr Witt is supported by grant funding from the Agency for Healthcare Research and Quality (R18 HS27960).
Comment on
-
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials.J Am Coll Cardiol. 2023 Jan 3;81(1):16-30. doi: 10.1016/j.jacc.2022.10.008. Epub 2022 Oct 31. J Am Coll Cardiol. 2023. PMID: 36328154 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
